French S J, Bergin A, Sepple C P, Read N W, Rovati L
Centre for Human Nutrition, University of Sheffield, Northern General Hospital, UK.
Int J Obes Relat Metab Disord. 1994 Nov;18(11):738-41.
The aim of this paper was to investigate the effects of the CCK, a receptor antagonist loxiglumide on food intake, hunger and fullness in humans. A double blind, placebo controlled, cross-over test was carried out, with subjects taking one loxiglumide or one placebo tablet three times a day, 15 min before main meals or at comparable intervals. The work was carried out at the Centre for Human Nutrition, Northern General Hospital, University of Sheffield, on 11 healthy, normal weight, male and female volunteers. The following were measured: weighted-intake measurement of food intake during drug and placebo treatment; laboratory test of food intake on day three of each treatment; hunger and fullness ratings throughout this meal. A small, non-significant, increase in food intake as measured by the weighed intake diaries (8577 +/- 636 vs 7895 +/- 569 kJ (2049 +/- 152 vs 1886 +/- 136 kcal); P = 0.17) was seen during loxiglumide treatment, but no effect on food consumption from the evening test meal was observed and no effect on feelings of hunger and fullness before or after this meal was seen. These results do not support the hypothesis that, in the free feeding situation, endogenously released CCK is involved in the reduction of food intake or inhibition of hunger. However, a different dose of route of administration or a larger group of subjects may reveal an effect of loxiglumide on feeding in humans.
